project id: TCGA-TGCT; case submitter id: TCGA-W4-A7U4; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 2.0; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 7.3; age at index: 23; days to birth: -8518; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1988; age at diagnosis: 8518; ajcc clinical m: M0; ajcc clinical n: N0; ajcc clinical stage: Stage I; ajcc clinical t: T1; ajcc pathologic m: M0; ajcc pathologic n: NX; ajcc pathologic t: T2; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 738.0; icd 10 code: C62.90; last known disease status: not reported; morphology: 9070/3; primary diagnosis: Embryonal carcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Testis, NOS; synchronous malignancy: No; tissue or organ of origin: Testis, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 650; days to sample procurement: 0; portion submitter id: TCGA-W4-A7U4-01A-12; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 80.0;